Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.72 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.72 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.72 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.72 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.72 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.55 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | GJB2 | P29033 | 1/20 | 0.53 |
| ▸ | CDC25B | P30305 | 6/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7155707 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL14021065 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7545074 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL23343941 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL11446298 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL24122546 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6298172 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL3065395 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL7148930 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL19400314 | 1.00 | SSTR1 (0.72) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3530663-B1 | PROCESS FOR PREPARING GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS | SUNSHINE BIOPHARMA INC (CA) | 2021-08-11 | — | — | EP | disclosed |
| US-20210087216-A1 | GLYCOSIDIC DERIVATIVES OF TREPROSTINIL | AOP ORPHAN IP AG (LI) | 2021-03-25 | — | — | US | disclosed |
| EP-3530663-A1 | PROCESS FOR PREPARING GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS | Advanomics Corp. (CA) | 2019-08-28 | — | — | EP | disclosed |
| US-10272065-B2 | Gem-difluorinated C-glycoside compounds as anti-cancer agents | Benoit & Côté (CA) | 2019-04-30 | — | — | US | disclosed |
| US-10272065-B2 | Gem-difluorinated C-glycoside compounds as anti-cancer agents | Benoit & Côté (CA) | 2019-04-30 | — | — | US | disclosed |
| US-20150353573-A1 | GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS AS ANTI-CANCER AGENTS | ADVANOMICS CORPORATION (CA) | 2015-12-10 | — | — | US | disclosed |
| EP-2943497-A1 | GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS AS ANTI-CANCER AGENTS | Advanomics Corp. (CA) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014107803-A1 | GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS AS ANTI-CANCER AGENTS | ADVANOMICS CORPORATION (CA) | 2014-07-17 | — | — | WO | disclosed |
| US-8236935-B2 | Gem-difluorinated C-glycoside compounds derived from podophyllotoxin, their preparation and their applications | INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA) (FR) | 2012-08-07 | — | — | US | disclosed |
| US-20090318675-A1 | NOVEL GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS DERIVED FROM PODOPHYLLOTOXIN, THEIR PREPARATION AND THEIR APPLICATIONS | SUNSHINE BIOPHARMA INC. (CA) | 2009-12-24 | — | — | US | disclosed |
| WO-2007125194-A1 | NEW GEM-DIFLUORO C-GLYCOSIDE COMPOUNDS DERIVED FROM PODOPHYLLOTOXIN, PREPARATION AND USES THEREOF | INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA) (FR) | 2007-11-08 | — | — | WO | disclosed |
| EP-0688329-B1 | NOVEL PHOSPHOLIPID-SACCHARIDE CONJUGATES | GENZYME CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| US-5627270-A | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same | TRUSTEES OF PRINCETON UNIVERSITY (US) | 1997-05-06 | — | — | US | disclosed |
| US-5354853-A | Phospholipid-saccharide conjugates | GENZYME CORPORATION (US) | 1994-10-11 | — | — | US | disclosed |
| US-4207413-A | ARTIFICIAL SWEETENER | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087216-A1 | GLYCOSIDIC DERIVATIVES OF TREPROSTINIL | TREH, PTGIR, PTGIS | SSTR1 779/4885SSTR2 716/4885SSTR4 935/4885 |
| US-20150353573-A1 | GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS AS ANTI-CANCER AGENTS | GMNN, DDOST, MAGT1 | SSTR1 4366/4885SSTR2 4096/4885SSTR4 3802/4885 |
| US-20090318675-A1 | NOVEL GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS DERIVED FROM PODOPHYLLOTOXIN, THEIR PREPARATION AND THEIR APPLICATIONS | GLRA3, GMNN, B3GAT3 | SSTR1 2007/4885SSTR2 2494/4885SSTR4 2156/4885 |
| US-10272065-B2 | Gem-difluorinated C-glycoside compounds as anti-cancer agents | GMNN, DDOST, MAGT1 | SSTR1 4366/4885SSTR2 4096/4885SSTR4 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.